Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

[1]  S. Rudikoff,et al.  Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. , 2004, Blood.

[2]  S. Franco,et al.  Clinical Experience with Trastuzumab (Herceptin) , 2003, The breast journal.

[3]  J. Grandis,et al.  Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer , 2003, Expert review of anticancer therapy.

[4]  Carlos Arteaga,et al.  Targeting HER1/EGFR: a molecular approach to cancer therapy. , 2003, Seminars in oncology.

[5]  K. Yee,et al.  Advances in targeted therapy for chronic myeloid leukemia , 2003, Expert review of anticancer therapy.

[6]  M. Hidalgo,et al.  Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva). , 2003, Seminars in oncology.

[7]  A. Olshen,et al.  Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. , 2003, Cancer research.

[8]  Hao Wang,et al.  Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Sledge.  Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer. , 2003, Seminars in oncology.

[10]  J. Baselga,et al.  ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  T. Holyoake,et al.  Is there a cloud in the silver lining for imatinib? , 2003, British Journal of Cancer.

[12]  C. Arteaga,et al.  The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. , 2003, Seminars in oncology.

[13]  G. Hortobagyi,et al.  Growth factor receptors in breast cancer: potential for therapeutic intervention. , 2003, The oncologist.

[14]  M. Sliwkowski,et al.  Perspectives on Anti-HER Monoclonal Antibodies , 2002, Oncology.

[15]  J. Baselga,et al.  HER-Targeted Tyrosine-Kinase Inhibitors , 2002, Oncology.

[16]  C. Cordon-Cardo,et al.  17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  L. Neckers.  Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  L. Neckers,et al.  Hsp90 inhibitors as novel cancer chemotherapeutic agents. , 2002, Trends in molecular medicine.

[19]  B. Fakler,et al.  Prestin, the Motor Protein of Outer Hair Cells , 2002, Audiology and Neurotology.

[20]  F. Mandelli,et al.  Advances in the understanding and management of acute promyelocytic leukemia. , 2002, Reviews in clinical and experimental hematology.

[21]  R. Salgia,et al.  Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  F. Khuri,et al.  ZD1839 (Iressa) in non-small-cell lung cancer. , 2002, Clinical lung cancer.

[23]  D. Berry,et al.  Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[25]  N. Bander,et al.  In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. , 2000, Cancer research.

[26]  M. Rusiniak,et al.  Current issues in the management of acute promyelocytic leukemia , 2000, Annals of Hematology.

[27]  N. Rosen,et al.  Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. , 2000, Cancer research.

[28]  A. Ebert,et al.  Expression and Function of Egf-Related Peptides and Their Receptors in Gynecological Cancer - From Basic Science to Therapy? , 2000, Journal of receptor and signal transduction research.

[29]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[30]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[31]  C. Cordon-Cardo,et al.  Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  D. Goodenough,et al.  Theoretical limitations in the immunodiagnostic imaging of cancer with computed tomography and nuclear scanning. , 1980, Cancer research.